Literature DB >> 14601091

Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.

Junko Uchikawa1, Tanri Shiozawa, Hsien-Chang Shih, Tsutomu Miyamoto, Yu-Zhen Feng, Hiroyasu Kashima, Kenji Oka, Ikuo Konishi.   

Abstract

BACKGROUND: To examine the steroid hormone dependent growth mechanism of human endometrial hyperplasia and carcinoma, expression levels of steroid receptor cofactors, such as coactivators (steroid receptor coactivator 1 [SRC-1] and p300/cyclic AMP-response element-binding protein (p300/CBP]) and corepressors (nuclear receptor corepressor [NCoR] and silencing mediator for retinoid and thyroid-hormone receptors [SMRT]), were investigated.
METHODS: The expression levels of cofactors were examined immunohistochemically using 20 samples of normal endometria, 36 samples of hyperplastic endometria, and 58 of malignant endometria and were compared with the expression levels of estrogen receptor (ER), progesterone receptor (PR), and a proliferation marker, Ki-67.
RESULTS: In samples of normal endometria, the expression of coactivators was observed diffusely in glandular cells in the proliferative phase, with a mean positivity index (PI) of 81.8 for SRC-1 and 91.3 for p300/CBP, whereas expression levels decreased in endometrial hyperplasia (PI: SRC-1, 58.9; p300/CBP, 83.8) and endometrial carcinoma (PI: SRC-1, 45.0; p300/CBP, 55.4). In endometrial hyperplasia, there was a significant correlation between the expression of ER and SRC-1 or p300/CBP. In contrast, there were no significant statistical or topologic correlations between the expression of coactivators and the expression of ER/PR in endometrial carcinoma. The expression of corepressors generally was limited, except for elevated expression of NCoR in endometrial hyperplasia (PI, 23.8).
CONCLUSIONS: The current study showed that expression levels of the steroid receptor coactivators SRC-1 and p300/CBP were reduced in endometrial carcinoma compared with normal and hyperplastic endometrium. In addition, topologic coexpression of both coactivators and ER/PR was lost in endometrial carcinoma. Accordingly, limited response to sex steroids in patients with endometrial carcinoma may be ascribed to the dissociation of cofactors and ER/PR. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601091     DOI: 10.1002/cncr.11760

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Steroid receptor coactivators as therapeutic targets in the female reproductive system.

Authors:  Maria M Szwarc; John P Lydon; Bert W O'Malley
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-04       Impact factor: 4.292

2.  Structural basis for retinoic X receptor repression on the tetramer.

Authors:  Haitao Zhang; Lili Chen; Jing Chen; Hualiang Jiang; Xu Shen
Journal:  J Biol Chem       Date:  2011-05-24       Impact factor: 5.157

3.  Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis.

Authors:  Z Zelenko; L Aghajanova; J C Irwin; Linda C Giudice
Journal:  Reprod Sci       Date:  2011-12-02       Impact factor: 3.060

4.  Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.

Authors:  Sema Bircan; Arzu Ensari; Sibel Ozturk; Nural Erdogan; Ilkkan Dundar; Firat Ortac
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

Review 5.  The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction.

Authors:  Maria M Szwarc; Ramakrishna Kommagani; Bruce A Lessey; John P Lydon
Journal:  Biol Reprod       Date:  2014-10-08       Impact factor: 4.285

6.  Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium.

Authors:  Akihisa Suzuki; Akiko Horiuchi; Kenji Oka; Tsutomu Miyamoto; Hiroyasu Kashima; Tanri Shiozawa
Journal:  Virchows Arch       Date:  2010-02-13       Impact factor: 4.064

7.  Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.

Authors:  Ratna K Vadlamudi; Seetharaman Balasenthil; Russell R Broaddus; Jan-Ake Gustafsson; Rakesh Kumar
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

Review 8.  Deconstructing repression: evolving models of co-repressor action.

Authors:  Valentina Perissi; Kristen Jepsen; Christopher K Glass; Michael G Rosenfeld
Journal:  Nat Rev Genet       Date:  2010-02       Impact factor: 53.242

Review 9.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.

Authors:  Jianming Xu; Ray-Chang Wu; Bert W O'Malley
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 10.  The function of steroid receptor coactivator-1 in normal tissues and cancer.

Authors:  Claire A Walsh; Li Qin; Jean Ching-Yi Tien; Leonie S Young; Jianming Xu
Journal:  Int J Biol Sci       Date:  2012-03-07       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.